Jan Godzinski
Overview
Explore the profile of Jan Godzinski including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
788
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Flaadt T, Lemelle L, Abele M, Virgone C, Ben-Ami T, Kachanov D, et al.
Lung Cancer
. 2025 Feb;
201:108449.
PMID: 39999637
Background And Aims: NUT carcinoma (NC) is a sporadic, highly aggressive tumor that primarily affects children, adolescents, and young adults and is characterized by the presence of somatic NUTM1 rearrangements....
2.
Owczarzak M, Biela M, Paplicki M, Rapala M, Jakubaszko-Jablonska J, Kozakiewicz M, et al.
J Clin Med
. 2024 Oct;
13(20).
PMID: 39458087
The COVID-19 pandemic affected the health of millions of people, both directly through infection and indirectly through delayed diagnosis and treatment of non-COVID-19 illnesses. The aim of this study was...
3.
Roganovic J, Virgone C, Ben-Ami T, Reguerre Y, Ferrari A, Orbach D, et al.
Clin Transl Oncol
. 2024 Sep;
PMID: 39225960
Purpose: Within the Paediatric Rare Tumours Network-European Registry (PARTNER) project, we aimed to evaluate the situation on the registration and management of paediatric patients affected by very rare tumours (VRT)...
4.
Sudour-Bonnange H, van Tinteren H, Ramirez-Villar G, Godzinski J, Irtan S, Gessler M, et al.
Br J Cancer
. 2024 Jul;
131(6):972-981.
PMID: 39080350
Background: Among patients with nephroblastoma, those with bilateral disease are a unique population where maximising tumour control must be balanced with preserving renal parenchyma. Methods: The SIOP 2001 protocol recommended...
5.
Glick R, Romao R, Pachl M, Kotagal M, Buchanan A, Murphy A, et al.
Pediatr Blood Cancer
. 2024 May;
:e31118.
PMID: 38809413
Pediatric renal tumors are among the most common pediatric solid malignancies. Surgical resection is a key component in the multidisciplinary therapy for children with kidney tumors. Therefore, it is imperative...
6.
Tracy E, Vasconcelos-Castro S, Malogolowkin M, Loh A, Kotagal M, Glick R, et al.
Pediatr Blood Cancer
. 2023 Apr;
70 Suppl 2:e30338.
PMID: 37057802
Although general treatment approaches for Wilms tumor differ between Children's Oncology Group and Société Internationale d'Oncologie Pédiatrique-Renal Tumors Study Group protocols, complex tumors that may be candidates for nephron sparing...
7.
de Aguirre-Neto J, de Camargo B, van Tinteren H, Bergeron C, Brok J, Ramirez-Villar G, et al.
JCO Glob Oncol
. 2022 May;
8:e2100425.
PMID: 35537105
Purpose: International comparisons of patient demographics, tumor characteristics, and survival can shed light on areas for health care system improvement. The International Society of Pediatric Oncology Wilms Tumor 2001 trial/study...
8.
Groenendijk A, van Tinteren H, Jiang Y, de Krijger R, Vujanic G, Godzinski J, et al.
Eur J Cancer
. 2022 Jan;
163:88-97.
PMID: 35042071
Purpose: Society of International Pediatric Oncology - Renal Tumor Study Group (SIOP-RTSG) treatment recommendations for relapsed Wilms tumour (WT) are stratified by the intensity of first-line treatment. To explore the...
9.
Styczewska M, Krawczyk M, Brecht I, Haug K, Izycka-Swieszewska E, Godzinski J, et al.
Cancers (Basel)
. 2021 Aug;
13(15).
PMID: 34359769
Melanotic Neuroectodermal Tumor of Infancy (MNTI) is a very rare pediatric neoplasm of neural crest origin. In most cases, it develops in infants as a localized tumor of the maxilla,...
10.
Groenendijk A, Spreafico F, de Krijger R, Drost J, Brok J, Perotti D, et al.
Cancers (Basel)
. 2021 Jul;
13(13).
PMID: 34201787
In high-income countries, the overall survival of children with Wilms tumors (WT) is ~90%. However, overall, 15% of patients experience tumor recurrence. The adverse prognostic factors currently used for risk...